BostonGene Showcases Groundbreaking Research at Major Symposium
WALTHAM, Mass.-- BostonGene, a leading provider of AI-driven molecular and immune profiling solutions, recently shared exciting news at the 2024 San Antonio Breast Cancer Symposium (SABCS) where three abstracts of significant research have been accepted for presentation. This noteworthy event will take place at the Henry B. Gonzalez Convention Center, focusing on innovative approaches in breast cancer treatment.
BostonGene's Commitment to Innovative Treatment Strategies
During the symposium, BostonGene is eager to demonstrably highlight their advancements in molecular profiling. Nathan Fowler, MD, the Chief Medical Officer at BostonGene, conveyed excitement regarding their research. “We’re excited to present our research at the 2024 SABCS, underscoring BostonGene’s commitment to leveraging molecular profiling as a transformative tool in breast cancer treatment,” he stated.
Understanding the Importance of Molecular Profiling
The research conducted by BostonGene zeroes in on transcriptomic classification, a pioneering avenue intended to cultivate more effective treatment pathways and establish new benchmarks in precision oncology. These efforts aim to enrich the understanding of breast cancer and tailor treatments to individual patient needs accurately.
Highlighting Key Research Findings
Key abstracts presented at the symposium include various aspects of breast cancer analysis, each addressing critical areas of treatment and understanding of the disease. The specifics of the studies reveal not only the intricacies involved but also the potential for improving patient outcomes through targeted therapies.
Exploring Correlation Between FISH and NGS
The first abstract, numbered 1760, showcases the evaluation of the correlation between fluorescence in situ hybridization (FISH) and next-generation sequencing (NGS) when assessing ERBB2 alterations in breast cancer. This study demonstrates the advantages of NGS in revealing significant mutations in non-amplified samples, pointing to the potential for more personalized treatment applications.
Antibody-Drug Conjugates in Invasive Lobular Carcinoma
The second highlight, abstract 2476, focuses on a comprehensive analysis of antibody-drug conjugate (ADC) target expressions within various subtypes of invasive lobular carcinoma. This research aims to spotlight the distinct expression landscapes of potential ADC targets, emphasizing the necessity for tailored treatment in optimizing efficacy and safety.
Utilizing Liquid Biopsy for Treatment Predictions
The third abstract, numbered 1521, elucidates a phase 2 study that investigates the levels of circulating tumor DNA (ctDNA) as a predictive marker for patients with metastatic breast cancer. This innovative research utilizes BostonGene's liquid biopsy test, showing promise in predicting treatment switches based on ctDNA levels, potentially extending disease control and improving survival rates.
Engagement Opportunities at SABCS
BostonGene will also maintain a presence at booth 1317 during the symposium, welcoming attendees to learn more about their innovative approaches and discuss collaborative opportunities. For those interested in further dialogue, Erin Keleher is available for scheduling meetings.
About BostonGene Corporation
BostonGene is at the forefront of biotechnology, specializing in the integration of advanced computational biology with precision medicine. Since its inception in 2015, the company has continually strived for innovation aimed at improving patient care and accelerating drug development. Their AI-powered multiomics platform effectively decodes the molecular profiles of cancer patients and vets out the best treatment options according to individual cases. With the backing of a CLIA-certified and CAP-accredited high-complexity laboratory, BostonGene is dedicated to empowering precision medicine and enhancing oncology research.
Frequently Asked Questions
What recent research did BostonGene present at SABCS 2024?
BostonGene presented three abstracts focusing on molecular profiling, ADC target expressions, and circulating tumor DNA in breast cancer treatment at SABCS 2024.
How does molecular profiling enhance breast cancer treatment?
Molecular profiling allows for personalized treatment plans by identifying the specific genomic alterations present in individual tumors, thus optimizing therapeutic strategies.
What were the key findings regarding ERBB2 analysis?
The research demonstrated that NGS could detect significant mutations in ERBB2 status that traditional methods like FISH might miss, offering new insights for personalized treatment.
How can patients benefit from the ctDNA study?
The ctDNA levels can indicate when a treatment switch may be necessary, helping to improve patient monitoring and potentially prolonging survival rates.
Where can I learn more about BostonGene's innovations?
You can explore BostonGene's website for more information on their research and advancements in precision medicine and oncology.
